Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MEK inhibition leads to the relieve of MAPK-dependent negative feedback on the pathway and consequential induction of RTK signaling”
In the citing paper
“rapid onset of resistance is a limit to combination therapies in KRAS mutated CRC”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 4×
“The only known catalytic substrates for both MEK1/2 isoforms are the MAP kinases ERK1 and ERK2 [4-25].”
BackgroundInfluentialDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 1×
“Activating mutations in KRAS (exon 2, 3 and 4) and NRAS (exon 2 , 3 and 4) occur in about 55% of metastatic CRC, while mutations in HRAS seem to occur infrequently [59-67].”
BackgroundSelf-citationUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
RAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902 · cited 2×
“MEK proteins belong to a family of enzymes that lie upstream to their specific MAPK targets in each of the four MAP kinase signalling pathways and so far 7 MEK enzymes have been identified [1,5].”
BackgroundVan Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882 · cited 1×
“Activating mutations in KRAS (exon 2, 3 and 4) and NRAS (exon 2 , 3 and 4) occur in about 55% of metastatic CRC, while mutations in HRAS seem to occur infrequently [59-67].”
BackgroundSelf-citationHeinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224
Research works printed but not linked: 52
- McCubrey, 2007, Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance, Biochim Biophys Acta, 1773, 1263, 10.1016/j.bbamcr.2006.10.001 · DOI · Paper page
- Cowley, 1994, Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3cells, Cell, 77, 841, 10.1016/0092-8674(94)90133-3 · DOI · Paper page
- Sebolt-Leopold, 2004, MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors, Curr Pharm Des, 10, 1907, 10.2174/1381612043384439 · DOI
- Friday, 2008, Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy, Clin Cancer Res, 14, 342, 10.1158/1078-0432.CCR-07-4790 · DOI · Paper page
- Montagut, 2009, Targeting the RAF–MEK–ERK pathway in cancer therapy, Cancer Lett, 283, 125, 10.1016/j.canlet.2009.01.022 · DOI · Paper page
- Neuzillet, 2013, Targeting the Ras–ERK pathway in pancreatic adenocarcinoma, Cancer Metastasis Rev, 32, 147, 10.1007/s10555-012-9396-2 · DOI
- Bernards, 2004, GAP control: regulating the regulators of small GTPases, Trends Cell Biol, 14, 377, 10.1016/j.tcb.2004.05.003 · DOI · Paper page
- Fischmann, 2009, Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors, Biochemistry, 48, 2661, 10.1021/bi801898e · DOI · Paper page
- Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766 · DOI · Paper page
- Marks, 2008, Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signalling pathway genes in lung adenocarcinoma, Cancer Res, 68, 5524, 10.1158/0008-5472.CAN-08-0099 · DOI · Paper page
- Murugan, 2009, MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas, Cell Cycle, 8, 2122, 10.4161/cc.8.13.8710 · DOI · Paper page
- Flaherty, 2012, Improved survival with MEK inhibition in BRAF-mutated melanoma, N Engl J Med, 367, 107, 10.1056/NEJMoa1203421 · DOI · Paper page
- Zhao, 2014, The clinical development of MEK inhibitors, Nat Rev Clin Oncol, 83, 1
- Downward, 1994, The GRB2/Sem-5 adaptor protein, FEBS Lett, 338, 113, 10.1016/0014-5793(94)80346-3 · DOI · Paper page
- Avraham, 2000, RAFTK/Pyk2-mediated cellular signaling, Cell Signal, 12, 123, 10.1016/S0898-6568(99)00076-5 · DOI · Paper page
- Sondermann, 2004, Structural analysis of autoinhibition in the Ras activator Son of sevenless, Cell, 119, 393, 10.1016/j.cell.2004.10.005 · DOI · Paper page
- Margarit, 2003, Structural evidence for feedback activation by Ras. GTP of the Ras-specific nucleotide exchange factor SOS, Cell, 112, 685, 10.1016/S0092-8674(03)00149-1 · DOI · Paper page
- Mitin, 2005, Signaling interplay in Ras superfamily function, Curr Biol, 15, R563, 10.1016/j.cub.2005.07.010 · DOI · Paper page
- Ledwith, 1990, Antisense-fos RNA causes partial reversion of the transformed phenotypes induced by the c-Ha-ras oncogene, Mol Cell Biol, 10, 1545, 10.1128/MCB.10.4.1545 · DOI
- Haystead, 1992, Ordered phosphorylation of p42 mapk by MAP kinase kinase, FEBS Lett, 306, 17, 10.1016/0014-5793(92)80828-5 · DOI · Paper page
- Marks, 2008, Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma, Cancer Res, 68, 5524, 10.1158/0008-5472.CAN-08-0099 · DOI · Paper page
- Janku, 2010, Targeted therapy in non-small-cell lung cancer is it becoming a reality?, Nat Rev Clin Oncol, 7, 401, 10.1038/nrclinonc.2010.64 · DOI · Paper page
- Paez, 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 304, 497, 10.1126/science.1099314 · DOI · Paper page
- Thomas, 2005, Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors, Cold Spring Harb Symp Quant Biol, 70, 73, 10.1101/sqb.2005.70.056 · DOI · Paper page
- Pao, 2005, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib, PLoS Med, 2, e17, 10.1371/journal.pmed.0020017 · DOI · Paper page
- Roberts, 2013, KRAS mutation: should we test for it, and does it matter?, J Clin Oncol, 31, 1112, 10.1200/JCO.2012.43.0454 · DOI · Paper page
- Marchetti, 2011, Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations, J Clin Oncol, 29, 3574, 10.1200/JCO.2011.35.9638 · DOI · Paper page
- Paik, 2011, Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations, J Clin Oncol, 29, 2046, 10.1200/JCO.2010.33.1280 · DOI · Paper page
- Sen, 2012, Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib, Sci Transl Med, 4, 10.1126/scitranslmed.3003513 · DOI · Paper page
- Heidorn, 2010, Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF, Cell, 140, 209, 10.1016/j.cell.2009.12.040 · DOI · Paper page
- Martinelli, 2010, Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells, Clin Cancer Res, 16, 10.1158/1078-0432.CCR-10-0923 · DOI · Paper page
- Morgillo, 2011, Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors, PLoS One, 6, e28841, 10.1371/journal.pone.0028841 · DOI
- Zhang, 2010, Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells, Carcinogenesis, 31, 577, 10.1093/carcin/bgq020 · DOI · Paper page
- Ji-Young, 2013, Enhanced apoptosis by pemetrexed and simvastatin in malignant mesothelioma and lung cancer cells by reactive oxygen species-dependent mitochondrial dysfunction and Bim induction, Invest New Drugs, 31
- Hainsworth, 2010, A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens, J Thorac Oncol, 5, 1630, 10.1097/JTO.0b013e3181e8b3a3 · DOI · Paper page
- Yoon, 2010, KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach, Mol Carcinog, 49, 353, 10.1002/mc.20607 · DOI · Paper page
- Troiani, 2012, Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells, Br J Cancer, 106, 1648, 10.1038/bjc.2012.129 · DOI · Paper page
- Little, 2012, Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling, Biochem Soc Trans, 40, 73, 10.1042/BST20110647 · DOI
- Jänne PA, van den Heuvel M, Barlesi M, Cobo M, Mazieres J, Crinò L et al. Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: results from the phase III SELECT-1. In: LBA45 ESMO meeting; 2016. · DOI
- Thiery, 2003, Epithelial-mesenchymal transitions in development and pathologies, Curr Opin Cell Biol, 6, 740, 10.1016/j.ceb.2003.10.006 · DOI · Paper page
- Morgillo, 2011, Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors, Br J Cancer, 105, 382, 10.1038/bjc.2011.244 · DOI · Paper page
- Buonato, 2014, ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition, Cancer Res, 74, 309, 10.1158/0008-5472.CAN-12-4721 · DOI · Paper page
- Eberlein, 2015, Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models, Cancer Res, 75, 2489, 10.1158/0008-5472.CAN-14-3167 · DOI · Paper page
- Tricker, 2015, Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer, Cancer Discov, 5, 960, 10.1158/2159-8290.CD-15-0063 · DOI · Paper page
- Ciardiello, 2008, EGFR antagonists in cancer treatment, N Engl J Med, 358, 1160, 10.1056/NEJMra0707704 · DOI · Paper page
- Douillard, 2010, Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study, J Clin Oncol, 28, 4697, 10.1200/JCO.2009.27.4860 · DOI · Paper page
- Bardelli, 2010, Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer, J Clin Oncol, 8, 1254, 10.1200/JCO.2009.24.6116 · DOI · Paper page
- Schwartzberg, 2014, J Clin Oncol, 32, 2240, 10.1200/JCO.2013.53.2473 · DOI · Paper page
- De Roock, 2011, KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer, Lancet Oncol, 12, 594, 10.1016/S1470-2045(10)70209-6 · DOI · Paper page
- Troiani, 2013, Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance, Expert Opin Biol Ther, 13, 241, 10.1517/14712598.2012.756469 · DOI
- Little, 2011, Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells, Sci Signal, 4, 10.1126/scisignal.2001752 · DOI · Paper page
- Atreya, 2015, Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC), J Clin Oncol, 33, 10.1200/jco.2015.33.15_suppl.103 · DOI · Paper page
Cited by
KRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Huang, L., Jiang, S., & Shi, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00977-0 · Cited by 456
MEK inhibitors for the treatment of non-small cell lung cancer
Han, J., Liu, Y., Yang, S., Wu, X., Li, H., & Wang, Q. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01025-7 · Cited by 290
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases
Wang, H., Liu, Y., Wang, D., Xu, Y., Dong, R., Yang, Y., Lv, Q., Chen, X., & Zhang, Z. (2019) · Cells · doi:10.3390/cells8121597 · Cited by 279
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Zhu, C., Guan, X., Zhang, X., Luan, X., Song, Z., Cheng, X., Zhang, W., & Qin, J.-J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01629-2 · Cited by 231
Metadata
- Authors
- Martinelli, E., Morgillo, F., Troiani, T., & Ciardiello, F.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 53
- Pages
- 61-69
- ISSN
- 0305-7372
- Cited by
- 146
- References
- 30
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- Associazione Italiana per la Ricerca sul Cancro (14800)
- MFAG (17778)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. https://app.cochat.ai/papers/10.1016/j.ctrv.2016.12.001
- The paper
- Martinelli, E., Morgillo, F., Troiani, T., & Ciardiello, F. (2017). Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2016.12.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.